A galaxy populations study of a radio-selected protocluster at z~3.1

We present a population study of several types of galaxies within the protocluster surrounding the radio galaxy MRC0316-257 at z~3.1. In addition to the known population of Ly_alpha emitters (LAEs) and [OIII] emitters, we use colour selection techniques to identify protocluster candidates that are Lyman break galaxies (LBG) and Balmer break galaxies (BBGs). The radio galaxy field contains an excess of LBG candidates, with a surface density 1.6\pm0.3 times larger than found for comparable blank fields. This surface overdensity corresponds to an LBG volume overdensity of ~8\pm4. The BBG photometric redshift distribution peaks at the protocluster's redshift, but we detect no significant surface overdensity of BBG. This is not surprising because a volume overdensity similar to the LBGs would have resulted in a surface density of ~1.2 that found in the blank field. This could not have been detected in our sample. Masses and star formation rates of the candidate protocluster galaxies are determined using SED fitting. These properties are not significantly different from those of field galaxies. The galaxies with the highest masses and star formation rates are located near the radio galaxy, indicating that the protocluster environment influences galaxy evolution at z~3. We conclude that the protocluster around MRC0316-257 is still in the early stages of formation.Comment: 19 pages, 20 figures, accepted for publication in MNRA

Das planetarische politisch(e) Denken

No abstract

Factors influencing micronutrient bioavailability in biofortified crops

Dietary and human factors have been found to be the major factors influencing the bioavailability of micronutrients, such as provitamin A carotenoid (pVAC), iron, and zinc, in biofortified crops. Dietary factors are related to food matrix structure and composition. Processing can improve pVAC bioavailability by disrupting the food matrix but can also result in carotenoid losses. By degrading antinutrients, such as phytate, processing can also enhance mineral bioavailability. In in vivo interventions, biofortified crops have been shown to be overall efficacious in reducing micronutrient deficiency, with bioconversion factors varying between 2.3:1 and 10.4:1 for trans-β-carotene and amounts of iron and zinc absorbed varying between 0.7 and 1.1 mg/day and 1.1 and 2.1 mg/day, respectively. Micronutrient bioavailability was dependent on the crop type and the presence of fat for pVACs and on antinutrients for minerals. In addition to dietary factors, human factors, such as inflammation and disease, can affect micronutrient status. Understanding the interactions between micronutrients is also essential, for example, the synergic effect of iron and pVACs or the competitive effect of iron and zinc. Future efficacy trials should consider human status and genetic polymorphisms linked to interindividual variations

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Crafting Interiority, or the Evolutionary Objectivity of Vibrating Worlds: An Introduction to Adolf Behne’s “Biology and Cubism” (1915)

Sublimating the transgressive atrocities of modern warfare in an enigmatic text written within a year of the outbreak of WWI, art historian and architectural theorist Adolf Behne (1885-1948) takes recourse with humanity by tracing the uncanny thresholds between the human and non-human as proliferated by contemporary theories of biology. Disguised as a manifesto-like book review of biologist Jakob Johann von Uexküll’s Building Blocks of a Biological Worldview (1913), Behne’s “Biologie und Kubismus” (1915) engages Uexküll’s pluriversal worldview to complicate straightforward dualisms between artifice and nature, subtly imbricating the geopolitical and biopolitical spheres with the expressions of modern art. Dismantling impressionist art as lacking external-natural parallelism, Behne’s text champions expressionist art, whose forms and shapes evolve organically from a biologically-encoded creative interiority, as “true” art. A critical introduction to the author, text, and context prefaces the first English translation of “Biology and Cubism” more than a century after publication in the editorial outlet of artist-gallerist Herwarth Walden’s influential syndicate Der Sturm

<雜錄>新たに発見された玄奘三藏の遺骨

GP management checklist. (PDF 145 kb

Moral Hazard in Health Insurance: What We Know and How We Know It

© The Author(s) 2018. Published by Oxford University Press on behalf of European Economic Association. We describe research on the impact of health insurance on healthcare spending ("moral hazard"), and use this context to illustrate the value of and important complementarities between different empirical approaches. One common approach is to emphasize a credible research design; we review results from two randomized experiments, as well as some quasi-experimental studies. This work has produced compelling evidence that moral hazard in health insurance exists-that is, individuals, on average, consume less healthcare when they are required to pay more for it out of pocket-as well as qualitative evidence about its nature. These studies alone, however, provide little guidance for forecasting healthcare spending under contracts not directly observed in the data. Therefore, a second and complementary approach is to develop an economic model that can be used out of sample. We note that modeling choices can be consequential: different economic models may fit the reduced form but deliver different counterfactual predictions. An additional role of the more descriptive analyses is therefore to provide guidance regarding model choice